Neutrophil extracellular traps contribute to immune dysregulation in bullous pemphigoid via inducing B‐cell differentiation and antibody production. Issue 7 (21st June 2021)

• Record Type: Journal Article
• Authors: Fang, Hui; Shao, Shuai; Xue, Ke; Yuan, Xu; Qiao, Pei; Zhang, Jieyu; Cao, Tianyu; Luo, Yixin; Bai, Xiaocui; Li, Wenjing; Li, Caixia; Qiao, Hongjiang; Dang, Erle; Wang, Gang
• Is Part Of: FASEB journal. Volume 35:Issue 7(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-21
• Subjects: autoantibody -- autoimmunity -- B cell -- bullous pemphigoid -- neutrophil extracellular traps; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.202100145R
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: Bullous pemphigoid (BP), an autoimmune skin disease, is characterized by autoantibodies against hemidesmosomal proteins in the skin and mucous membranes. Neutrophils infiltrate BP skin lesions, however, their role in immune dysregulation remains unclear. We investigated whether BP involves aberrant neutrophil extracellular traps (NETs) formation in skin lesions and circulation; and examined the triggers and deleterious immuno‐inflammatory consequences. In the present study, we found that circulating NET‐related biomarker levels increased in serum and blister fluid of BP patients and significantly correlated with disease severity. Additionally, circulating neutrophils from BP patients displayed enhanced spontaneous NETs formation than healthy controls. In vitro, BP180‐NC16A immune complexes‐induced NETosis in neutrophils from BP patients, which was abrogated by Fcγ receptor and/or NADPH pathway blockade. Furthermore, the elevated levels of NETs from BP patients boosted autoantibody production by inducing B‐cell differentiation into plasma cells, mediated by MAPK P38 cascade activation. Together, our findings provide strong evidence that NETs are involved in a pathogenic loop, causing excessive differentiation of B cells and promotion of autoantibody production. Hence, targeting aberrant neutrophil responses will provide novel potential targets for the treatment of BP.